INTRODUCTION AND OBJECTIVES: Active Surveillance (AS) is widely accepted as the treatment of choice for favorable risk Prostate Cancer (PCa) . With the increasing number of men enrolling in AS it is important to understand the treatment outcomes in men who progress on AS and require definitive therapy in the form of radical prostatectomy (RP). We sought to examine the impact of delayed definitive treatment on oncologic outcomes in a cohort of men progressing on active surveillance to RP with a long-term follow up.
METHODS: We retrospectively reviewed a prospectively maintained database of men on AS from 01/1998-06/2014 at Princess Margaret Cancer Centre (PM). We identified patients on AS who underwent RP as definitive treatment. Biochemical recurrence (BCR) rate was compared to age and prostate specific antigen matched men undergoing immediate radical prostatectomy after a diagnosis of low risk disease who were candidates for active surveillance (control).
RESULTS: 1246 men met the PM's AS criteria at diagnosis, 250 patients (20%) progressed on AS to RP. The control group consist of 138 patients. There was no age difference between the 2 groups (P>0.05). At median follow up of 5.7 years (IQR 0.2 to 15.9), 16.7% of patients compared to 5.4% of controls experienced BCR (p¼0.005). Delayed RP was associated with a significantly shorter time to BCR compared to control group (median 3 years (0.3-15.1) vs. median 4.7 years, (0.2-13.0)). Clinical stage (T stage) at diagnosis was the only factor predictive of BCR on multivariate analysis.
CONCLUSIONS: In a non-pathologically matched cohort of patients on AS, patients who progressed to RP had a significantly higher BCR rate compared to patients who underwent immediate RP after diagnosis. While these findings are concerning, comparison of pathological outcomes, cancer specific survival and overall survival between the 2 groups will help us a better understanding the implication of higher BCR rate in delayed RP group.
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PD03-05 UPSTAGING IN RADICAL PROSTATECTOMY IN THE POST-PSA ERA: AN EFFECT OF DELAYED DIAGNOSIS OR BETTER PATIENT SELECTION?
Katherine Rotker*, Joseph Brito, Liz Edmund, Andres Matoso, Joseph Renzulli, Providence, RI INTRODUCTION AND OBJECTIVES: Serum prostate-specific antigen (PSA) levels had been widely used for screening of prostate cancer until May of 2012 when the U.S. Preventive Services Task Force (USPSTF) recommended against it based on concern for harm due to screening and over treatment of clinically insignificant prostate cancer. We aimed to study changes in radical prostatectomy findings after the issue of USPSTF recommendation against PSA screening.
METHODS: We retrieved and reviewed all consecutive RP performed at our institution immediately after the USPSTF issued its recommendation against PSA-based screening for prostate adenocarcinoma (5/2012) until 5/2015 (3 years). The control group included all RPs in the 3 years immediately before the USPSTF recommendation.
RESULTS: After 2012, the proportion of Gleason score 6 cancer decreased from 24.35% to 12.22% (p¼<0.01), the proportion of Gleason score 4+3¼7 increased from 12.45% to 20.58% (p¼0.01) and the proportion of Gleason score 8 or above increased from 8.4% to 13.18% (p¼0.04). Over this same time period, the proportion of RP with organ confined disease decreased from 71.43% to 62.7% (p¼0.01), the proportion of T3 disease increased from 29.2% to 38.26% (p¼0.01) and Vol. 195, No. 4S, Supplement, Friday, May 6, 2016 THE JOURNAL OF UROLOGY â e57
